We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Teva Pharmaceuticals (TEVA) ADR

Sell:$22.39 Buy:$22.41 Change: $0.21 (0.95%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$22.39
Buy:$22.41
Change: $0.21 (0.95%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$22.39
Buy:$22.41
Change: $0.21 (0.95%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Contact details

Address:
124 Dvora Hanevi'a St.
TEL AVIV-YAFO
6944020
Israel
Telephone:
+972 (3) 9148213
Website:
https://www.tevapharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TEVA
ISIN:
US8816242098
Market cap:
$24.74 billion
Shares in issue:
1.13 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Francis
    President, Chief Executive Officer, Director
  • Eliyahu Kalif
    Chief Financial Officer, Executive Vice President
  • Richard Daniell
    Executive Vice President - European Commercial
  • Christine Fox
    Executive Vice President - U.S. Commercial
  • Angus Grant
    Executive Vice President - Business Development
  • Eric Hughes
    Executive Vice President - Global R & D, Chief Medical Officer
  • David McAvoy
    Executive Vice President, Chief Legal Officer
  • Mark Sabag
    Executive Vice President - International Markets Commercial
  • Matthew Shields
    Executive Vice President - Global Operations
  • Vikki Conway
    Acting Head of Global Human Resources

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.